JP2017534645A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017534645A5 JP2017534645A5 JP2017525016A JP2017525016A JP2017534645A5 JP 2017534645 A5 JP2017534645 A5 JP 2017534645A5 JP 2017525016 A JP2017525016 A JP 2017525016A JP 2017525016 A JP2017525016 A JP 2017525016A JP 2017534645 A5 JP2017534645 A5 JP 2017534645A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- amino acid
- acid sequence
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14192519.8 | 2014-11-10 | ||
| EP14192519 | 2014-11-10 | ||
| PCT/EP2015/075877 WO2016075036A1 (en) | 2014-11-10 | 2015-11-06 | Anti-pdgf-b antibodies and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017534645A JP2017534645A (ja) | 2017-11-24 |
| JP2017534645A5 true JP2017534645A5 (enExample) | 2018-12-06 |
| JP6946184B2 JP6946184B2 (ja) | 2021-10-06 |
Family
ID=51947140
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017525016A Expired - Fee Related JP6946184B2 (ja) | 2014-11-10 | 2015-11-06 | 抗ｐｄｇｆ−ｂ抗体及び使用法 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10087246B2 (enExample) |
| EP (1) | EP3218400A1 (enExample) |
| JP (1) | JP6946184B2 (enExample) |
| KR (1) | KR20170082520A (enExample) |
| CN (1) | CN107148429B (enExample) |
| AR (1) | AR102593A1 (enExample) |
| AU (1) | AU2015345322A1 (enExample) |
| BR (1) | BR112017009792A2 (enExample) |
| CA (1) | CA2963723A1 (enExample) |
| IL (1) | IL251286A0 (enExample) |
| MX (1) | MX2017005975A (enExample) |
| RU (1) | RU2017120361A (enExample) |
| SG (1) | SG11201703426PA (enExample) |
| TW (1) | TW201630934A (enExample) |
| WO (1) | WO2016075036A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100256340A1 (en) | 2009-04-07 | 2010-10-07 | Ulrich Brinkmann | Trivalent, bispecific antibodies |
| EP3218402A1 (en) | 2014-11-10 | 2017-09-20 | F. Hoffmann-La Roche AG | Anti-il-1beta antibodies and methods of use |
| SG11201703428SA (en) | 2014-11-10 | 2017-05-30 | Hoffmann La Roche | Bispecific antibodies and methods of use in ophthalmology |
| CN107001456A (zh) | 2014-11-10 | 2017-08-01 | 豪夫迈·罗氏有限公司 | 抗ang2 抗体及使用方法 |
| CN107001482B (zh) | 2014-12-03 | 2021-06-15 | 豪夫迈·罗氏有限公司 | 多特异性抗体 |
| CN107849126B (zh) * | 2015-07-29 | 2022-04-08 | 阿勒根公司 | 仅有重链的抗ang-2抗体 |
| WO2020219774A1 (en) * | 2019-04-24 | 2020-10-29 | Magenta Therapeutics, Inc. | Anthracycline antibody-drug conjugates and uses thereof |
| EP4126940A1 (en) | 2020-03-30 | 2023-02-08 | F. Hoffmann-La Roche AG | Antibody that binds to vegf and pdgf-b and methods of use |
| JP2024505195A (ja) * | 2021-01-25 | 2024-02-05 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗ｐｄｇｆ－ｂ抗体及び肺動脈高血圧症（ｐａｈ）を治療するための使用方法 |
| TW202540203A (zh) * | 2024-01-08 | 2025-10-16 | 日商中外製藥股份有限公司 | 結合pdgf-b與pdgf-d的抗原結合分子及使用方法 |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4935343A (en) | 1986-08-08 | 1990-06-19 | Syntex (U.S.A.) Inc. | Monoclonal antibodies for interleukin-1β |
| ES2567198T3 (es) | 2003-01-24 | 2016-04-20 | Applied Molecular Evolution, Inc. | Antagonistas de la IL-1 beta humana |
| KR101471732B1 (ko) * | 2003-08-27 | 2014-12-16 | 옵쏘테크 코포레이션 | 안구의 혈관신생성 장애를 치료하기 위한 조합 치료법 |
| US20050282233A1 (en) * | 2004-03-05 | 2005-12-22 | Ludwig Institute For Cancer Research | Multivalent antibody materials and methods for VEGF/PDGF family of growth factors |
| DE102004062361A1 (de) * | 2004-12-10 | 2006-06-22 | Cocreate Software Gmbh & Co. Kg | Verfahren zur Ableitung von technischen Zeichungen aus 3D Modellen mit mindestens zwei kollidierenden 3D Körpern |
| BRPI0519596B1 (pt) * | 2004-12-21 | 2022-01-18 | Astrazeneca Ab | Agente de ligação alvejado, anticorpo monoclonal que se liga a angiopoietina-2, molécula de ácido nucleico, vetor, e, uso do agente de ligação alvejado |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| AR080794A1 (es) | 2010-03-26 | 2012-05-09 | Hoffmann La Roche | Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2 |
| AU2013283296A1 (en) | 2012-06-28 | 2015-02-05 | Molecular Partners Ag | Designed ankyrin repeat proteins binding to platelet-derived growth factor |
| NZ702201A (en) * | 2012-07-13 | 2018-01-26 | Roche Glycart Ag | Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases |
| CA2890471C (en) * | 2012-11-08 | 2021-07-27 | Clearside Biomedical, Inc. | Methods and devices for the treatment of ocular diseases in human subjects |
| AU2013343099A1 (en) * | 2012-11-09 | 2015-05-14 | Pfizer Inc. | Platelet-derived growth factor B specific antibodies and compositions and uses thereof |
| JO3405B1 (ar) * | 2013-01-09 | 2019-10-20 | Regeneron Pharma | الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها |
| SG10201800492PA (en) | 2013-04-29 | 2018-03-28 | Hoffmann La Roche | Human fcrn-binding modified antibodies and methods of use |
| RU2727639C2 (ru) | 2014-01-15 | 2020-07-22 | Ф.Хоффманн-Ля Рош Аг | Варианты fc-области с модифицированной способностью связываться с fcrn и с сохраненной способностью связываться с белком а |
| EP3218402A1 (en) | 2014-11-10 | 2017-09-20 | F. Hoffmann-La Roche AG | Anti-il-1beta antibodies and methods of use |
| CN107001456A (zh) | 2014-11-10 | 2017-08-01 | 豪夫迈·罗氏有限公司 | 抗ang2 抗体及使用方法 |
| SG11201703428SA (en) | 2014-11-10 | 2017-05-30 | Hoffmann La Roche | Bispecific antibodies and methods of use in ophthalmology |
-
2015
- 2015-11-06 JP JP2017525016A patent/JP6946184B2/ja not_active Expired - Fee Related
- 2015-11-06 CA CA2963723A patent/CA2963723A1/en not_active Abandoned
- 2015-11-06 RU RU2017120361A patent/RU2017120361A/ru not_active Application Discontinuation
- 2015-11-06 CN CN201580058634.5A patent/CN107148429B/zh not_active Expired - Fee Related
- 2015-11-06 MX MX2017005975A patent/MX2017005975A/es unknown
- 2015-11-06 BR BR112017009792A patent/BR112017009792A2/pt not_active Application Discontinuation
- 2015-11-06 AU AU2015345322A patent/AU2015345322A1/en not_active Abandoned
- 2015-11-06 EP EP15791586.9A patent/EP3218400A1/en not_active Ceased
- 2015-11-06 SG SG11201703426PA patent/SG11201703426PA/en unknown
- 2015-11-06 KR KR1020177011693A patent/KR20170082520A/ko not_active Withdrawn
- 2015-11-06 WO PCT/EP2015/075877 patent/WO2016075036A1/en not_active Ceased
- 2015-11-09 AR ARP150103646A patent/AR102593A1/es unknown
- 2015-11-09 TW TW104136908A patent/TW201630934A/zh unknown
-
2017
- 2017-03-20 IL IL251286A patent/IL251286A0/en unknown
- 2017-05-09 US US15/590,172 patent/US10087246B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017534645A5 (enExample) | ||
| JP2017534646A5 (enExample) | ||
| JP2020062036A5 (enExample) | ||
| JP2017534644A5 (enExample) | ||
| JP2017537896A5 (enExample) | ||
| RU2017120360A (ru) | Биспецифические антитела и способы их применения в офтальмологии | |
| JP2019501883A5 (enExample) | ||
| HRP20211528T1 (hr) | Trispecifični i/ili trovalentni vezujući proteini za prevenciju ili liječenje hiv infekcije | |
| RU2017120358A (ru) | Анти-il-1-бета антитела и способы их применения | |
| HRP20191584T1 (hr) | Anti-cd79b protutijela i načini uporabe | |
| JP2020511947A5 (enExample) | ||
| RU2019134352A (ru) | Новые биспецифические антигенсвязывающие молекулы, обладающие способностью специфически связываться с cd40 и fap | |
| RU2017120361A (ru) | Антитела к pdgf-b и способы их применения | |
| JP2020500538A5 (enExample) | ||
| JP2018537966A5 (enExample) | ||
| JP2014511179A5 (enExample) | ||
| JP2016512551A5 (enExample) | ||
| JP2019536806A5 (enExample) | ||
| HRP20200384T1 (hr) | Humanizirana anti-tau(ps422) protutijela i načini uporabe | |
| RU2020124153A (ru) | Гуманизированные антитела к cd19 человека и способы их применения | |
| JP2017504566A5 (enExample) | ||
| JP2011046732A5 (enExample) | ||
| FI3484915T3 (fi) | Uusia zikavirusepitooppeihin spesifisesti sitoutuvia vasta-aineita ja niiden käyttöjä | |
| JP2017528476A5 (enExample) | ||
| JP2015533795A5 (enExample) |